Centers, HSCD

Medicine & Life Sciences

1. Asthma 100%
2. Neoplasms 60%
3. Breast Neoplasms 52%
4. Melanoma 37%
5. Child 37%
6. Prostatic Neoplasms 36%
7. Prostate 34%
8. Respiratory Sounds 33%
9. Therapeutics 30%
10. Doxorubicin 30%
11. Drug Therapy 29%
12. Survival 29%
13. Cyclophosphamide 29%
14. 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one 26%
15. Non-Small Cell Lung Carcinoma 23%
16. Carcinoma 23%
17. Adenoma 22%
18. Cell Line 21%
19. Genes 21%
20. Serum 20%
21. Immunoglobulin E 20%
22. Cisplatin 20%
23. Lung 20%
24. Small Cell Lung Carcinoma 19%
25. In Vitro Techniques 18%
26. Placebos 17%
27. Bone Marrow Transplantation 17%
28. Pharmaceutical Preparations 17%
29. Neoplasm Metastasis 16%
30. Pharmacokinetics 16%
31. Bone Marrow 16%
32. Etoposide 15%
33. Skin 15%
34. Phenotype 15%
35. Recurrence 15%
36. Prostate-Specific Antigen 14%
37. Confidence Intervals 14%
38. Leukemia 14%
39. Integrins 14%
40. Single Nucleotide Polymorphism 14%
41. Parturition 14%
42. Acute Myeloid Leukemia 13%
43. Hypersensitivity 13%
44. Lymphocytes 13%
45. Selenium 12%
46. Population 12%
47. Interferons 12%
48. Radiotherapy 12%
49. Progression-Free Survival 11%
50. Colorectal Neoplasms 11%
51. Proteins 11%
52. Mitomycin 11%
53. Clinical Trials 11%
54. Contrast Media 11%
55. Genome-Wide Association Study 11%
56. Smoking 11%
57. Sarcoma 11%
58. Adrenal Cortex Hormones 11%
59. DNA 11%
60. Growth 11%
61. Immunotherapy 11%
62. Microbubbles 11%
63. Odds Ratio 10%
64. Acquired Immunodeficiency Syndrome 10%
65. Antibodies 10%
66. Apoptosis 10%
67. Busulfan 10%
68. Matrix Metalloproteinase 7 10%
69. Paclitaxel 10%
70. Colonic Neoplasms 10%
71. Incidence 10%
72. promatrilysin 10%
73. Interleukin-2 10%
74. Pediatrics 10%
75. Chemoprevention 10%
76. Bone and Bones 10%
77. Vincristine 10%
78. Biopsy 10%
79. Multiple Myeloma 10%
80. Skin Tests 10%
81. kalinin 9%
82. Cell Transplantation 9%
83. Kidney 9%
84. Transplants 9%
85. Tea 9%
86. Liver 9%
87. Respiratory System 9%
88. Liposomes 9%
89. Prostatic Intraepithelial Neoplasia 9%
90. Combination Drug Therapy 9%
91. Disease-Free Survival 9%
92. T-Lymphocytes 9%
93. Denosumab 8%
94. Biomarkers 8%
95. Mutation 8%
96. Keratins 8%
97. Tamoxifen 8%
98. Randomized Controlled Trials 8%
99. Adenocarcinoma 8%
100. Sexual and Gender Minorities 8%